Ascendis Pharma A/s American Depositary Shares | ASND

Daily Technical Analysis of Ascendis Pharma A/s American Depositary Shares

Ascendis Pharma A/s moved up less than 1% today. The market isn't being very decisive in its valuation of Biotechnology company. It looks like ASND may be interacting with an upward sloping support line. These can create nice entry points since it can have both momentum and support. ASND hasn't had very clear momentum over the last 3 months and has sort of been bouncing around so that doesn't make me feel very certain that it can punsh through the line.

If we get a reversal off of support and Ascendis Pharma A/s starts moving up, it can probably get to $168.84 at which point it'll need to break through that resistance level in order to keep moving higher. If it fails to bounce off this level and breaks down lower, it will most likely find the nearest support a the $137.9 at which point, it may have a chance of recovering from there.

Analyst Ratings for Ascendis Pharma A/s By Price Target And Rating

The analysts are pretty neutral on Ascendis Pharma A/S right now, so not much useful information here. The current Analysts Sentiment Score is 3.13. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. Cantor Fitzgerald announced that they are reiterating a rating of Overweight on 2024-05-03 and they set their price target at $173.00. JPMorgan Chase & Co. provided a price target boost of 1.8% to $170.00 from $167.00 on 2024-05-03. On 2024-04-22 Morgan Stanley reiterated their rating of Equal Weight and decided to decrease their price target by 0% down to $116.00. Wells Fargo & Company boosted their price targ by 32.65% to $260.00 on 2024-03-15. Wedbush provided a price target boost of 8.7% to $225.00 from $207.00 on 2024-02-08. On 2024-02-08 Citigroup increased their price target by 24.66% to $182.00. Jefferies Financial Group initiated a rating of Buy on 2023-12-20 and provided a price target of $150.00. On 2023-10-09 HC Wainwright reiterated their rating of Buy . Bank of America gave a boost to their price target and moved to $113.00 from $107.00 on 2023-09-07.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Ascendis Pharma A/S

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Ascendis Pharma A/S

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.